Curated News
By: NewsRamp Editorial Staff
October 02, 2026
SS Innovations Expands Robotic Surgery Platform Globally with 39% Revenue Growth
TLDR
- SSII revenue rose 39.4% to $13.9 million as it expands surgical robotics into 12 countries and pursues FDA and CE clearances.
- SS Innovations installed 30 SSi Mantra systems in Q2, reaching 224 installations and over 12,000 procedures across 12 countries.
- SS Innovations aims to make robotic surgery affordable and accessible worldwide, improving surgical care for more patients globally.
- SS Innovations is developing telesurgery capabilities for its SSi Mantra platform, potentially enabling remote operations across distances.
Impact - Why it Matters
SS Innovations' expansion into international markets and pursuit of FDA and CE clearances could significantly increase access to affordable robotic surgery worldwide. As the company grows its installed base and procedure volume, it may drive down costs and improve patient outcomes, particularly in emerging markets. This matters because robotic surgery has traditionally been expensive and limited to wealthy nations, but SSII's cost-effective solutions could democratize advanced surgical care, making it available to a broader population. For investors, the company's strong revenue growth and regulatory milestones could signal a compelling opportunity in the medtech sector.
Summary
SS Innovations International (NASDAQ: SSII) is making significant strides in the global surgical robotics market, expanding its SSi Mantra platform from its established base in India into international territories. The company reported strong second-quarter results, with revenue climbing 39.4% year over year to $13.9 million. During the quarter, SSII installed 30 systems, bringing its total installed base to 224 systems across 12 countries. Cumulatively, the company has supported more than 12,000 surgical procedures as of June 30, 2026. The SSi Mantra system is used across a range of specialties, including cardiac, urology, gynecology, general and thoracic surgery, and the company is also developing telesurgery capabilities to further enhance its offerings.
Looking ahead, SS Innovations is pursuing U.S. FDA 510(k) clearance and European CE marking, which could substantially broaden its addressable market and accelerate its global expansion. The company’s vision is to make robotic surgery affordable and accessible to a larger segment of the global population. Its product lineup includes the proprietary SSi Mantra surgical robotic system and the comprehensive suite of SSi Mudra surgical instruments, which support various procedures, including cardiac surgery. An American company headquartered in India, SS Innovations aims to expand the global presence of its technologically advanced, user-friendly, and cost-effective solutions.
For investors and industry watchers, the latest news and updates relating to SSII are available in the company’s newsroom at https://nnw.fm/SSII. The distribution of this content is handled by NetworkNewsWire (NNW), a specialized communications platform focused on financial news and content distribution. NNW is part of the Dynamic Brand Portfolio @ IBN, which offers a suite of services including wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only).
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, SS Innovations Expands Robotic Surgery Platform Globally with 39% Revenue Growth
